Xience V, Prime indicated for only three months of DAPT in EU
Abbott has announced that the Xience Prime and the Xience V everolimus-eluting coronary stent systems have received CE Mark in Europe for the use of dual antiplatelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. This is the shortest duration of DAPT for any major drug eluting stent (DES) in Europe.
Patients are prescribed DAPT, a combination of aspirin and an antiplatelet medication, following stent implantation. The most recent European Society of Cardiology (ESC) guidelines for myocardial revascularization, which were published in 2010, recommend that patients treated with a DES remain on DAPT for six to 12 months.
In the U.S., the indication for DAPT after stent implantation is still 12 months.
Patients are prescribed DAPT, a combination of aspirin and an antiplatelet medication, following stent implantation. The most recent European Society of Cardiology (ESC) guidelines for myocardial revascularization, which were published in 2010, recommend that patients treated with a DES remain on DAPT for six to 12 months.
In the U.S., the indication for DAPT after stent implantation is still 12 months.